Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs

American Journal of Veterinary Research

Volumn 72, Issue 8, 2011, Pages 1038-1045

  Hoh, Crystal M ^a   Smith, Stepanie A ^b   McMichael, Maureen A ^a   Byron, Julie K ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINORTHROMBOXANE B2; ACETYLSALICYLIC ACID; CREATININE;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; SINGLE DRUG DOSE; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; URINALYSIS; URINE LEVEL; VOMITING;

ANIMALS; ASPIRIN; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2;

CANIS FAMILIARIS;

EID: 80052750965     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.72.8.1038     Document Type: Article

References (49)

1. Karon BS, Wockenfus A, Scott R, et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin Chem 2008;54:1060-1065.
2. Craft RM, Chavez JJ, Bresee SJ, et al. A novel modifcation of the thromboelastogram assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004;143:301- 309.
3. Gurbel PA, Bliden K P, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study. Circulation 2007;115:3156-3164.
4. Faraday N, Becker DM, Yanek LR, et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006;98:774-779.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients (Erratum published in BMJ 2002;324:141). BMJ 2002;324:71-86.
6. Eikelboom J W, Hirsh J, Weitz JI, et al. Aspirin-resistant throm-boxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
7. Antithrombotic Trialists' Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860.
8. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA 2006;295:306-313.
9. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clodiprogrel in atherothrombotic disease. Circulation 2007;115:2196-2207.
10. Brainard BM, Meredith C P, Callan MB, et al. Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-infammatory drugs with various cyclooxygenase selectivities in dogs. Am J Vet Res 2007;68:251- 257.
11. Nielsen LA, Zois NE, Pedersen HD, et al. Platelet function in dogs: breed differences and effect of acetylsalicylic acid administration. Vet Clin Pathol 2007;36:267-273.
12. Mischke R, Keidel A. Infuence of platelet count, acetylsalicylic acid, von Willebrand's disease, coagulopathies, and hematocrit on results obtained using a platelet function analyser in dogs. Vet J 2003;165:43-52.
13. Mathie RT, Fleming JS, Barrow SE, et al. The haemodynamic effects of the thromboxane A2 receptor antagonist GR32191B during cardiopulmonary bypass in the dog. Perfusion 1995;10:403- 413.
14. Weinkle TK, Center SA, Randolph J F, et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993- 2002). J Am Vet Med Assoc 2005;226:1869-1880.
15. Lunsford K V, Mackin AJ. Thromboembolic therapies in dogs and cats: an evidence-based approach. Vet Clin North Am Small Anim Pract 2007;37:579-609.
16. Streppa HK, Jones CJ, Budsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-infammatory drugs in canine blood. Am J Vet Res 2002;63:91-94.
17. Weiss DJ, Brazzell JL. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Ve t Intern Med 2006;20:682-686.
18. Rackear D, Feldman B, Farver T, et al. The effect of three different dosages of acetylsalicylic acid on canine platelet aggregation. J Am Anim Hosp Assoc 1988;24:23-26.
19. Mullane KM, Dusting GJ, Salmon JA, et al. Biotransformation and cardiovascular effects of arachidonic acid in the dog. Eur J Pharmacol 1979;54:217-228.
20. Catella F, Healy D, Lawson J, et al. 11-dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A 1986;83:5861-5865.
21. Roberts LJ, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identifcation of twenty urinary metabolites. J Biol Chem 1981;256:8384-8393.
22. Patrono C, Ciabattoni G, Patrignani P, et al. Evidence for a renal origin of urinary thromboxane B2 in health and disease. Adv Prostaglandin Thromboxane Leukot Res 1983;11:493-498.
23. Chiabrando C, Rivoltella L, Martelli L, et al. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects. Biochim Biophys Acta 1992;1133:247-254.
24. Eikelboom J W, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid determinants and effect on cardiovascular risk. Circulation 2008;118:1705-1712.
25. McKellar QA, Nolan AM, Galbraith EA. Serum thromboxane generation by platelets in several domestic animal species. Br Vet J 1990;146:398-404.
26. Yamanaka S, Miura K, Yukimura T, et al. 11-dehydro thrombox-ane B2: a reliable parameter of thromboxane A2 production in dogs. Prostaglandins 1993;45:221-228.
27. Kawamura M, Harada Y, Katori M. Evaluation of plasma 11-de-hydro-thromboxane B2 as an indicator for thromboxane A2 synthesis in vivo in laboratory animals. Throm Res 1995;77:465- 474.
28. Baltzer WI, McMichael MA, Ruaux CG, et al. Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus. Am J Vet Res 2006;67:78-83.
29. Bode-Boger SM, Boger RH, Schubert M, et al. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J Clin Pharmacol 1998;54:707-714.
30. Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708.
31. Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin effcacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005;36:276-280.
32. Blois SL, Allen DG, Wood RD, et al. Effects of aspirin, carpro-fen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Am J Vet Res 2010;71:349-358.
33. Sessions JK, Reynolds LR, Budsberg SC. In vivo effects of car-profen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fuid in dogs with chronic osteoarthritis. Am J Vet Res 2005;66:812-817.
34. Jones CJ, Streppa HK, Harmon BG, et al. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fuid prostanoid synthesis in dogs. Am J Vet Res 2002;63:1527- 1531.
35. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygen-ase inhibition by low-dose aspirin is not refected consistently by platelet function assays: implications for aspirin resistance. J Am Coll Cardiol 2009;53:667-677.
36. Fitzgerald DJ, Fragetta J, FitzGerald GA. Prostaglandin endoper-oxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest 1988;82:1708-1713.
37. Tagari P, Callaghan DH, Black C, et al. Measurement of canine urinary thromboxanes by GC-MS and HPLC-RIA. Prostaglan-dins 1994;47:293-306.
38. Landolf R, Ciabattoni G, Patrignani P, et al. Increased throm-boxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:1965-1971.
39. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186.
40. Longhofer SL, Frisbie DD, Johnson HC, et al. Effects of throm-boxane synthetase inhibition on immune complex glomerulo-nephritis. Am J Vet Res 1991;52:480-487.
41. Catella F, FitzGerald GA. Paired analysis of urinary throm-boxane B2 metabolites in humans. Thromb Res 1987;47:647- 656.
42. Perneby C, Granstrom E, Beck O, et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. Thromb Res 1999;96:427-436.
43. Pratico D, Murphy N P, Fitzgerald DJ. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. J Pharmacol Exp Ther 1997;281:1178-1185.
44. Lawson JA, Patrono C, Ciabattoni G, et al. Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. Anal Biochem 1986;155:198-205.
45. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983;71:676-688.
46. Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007;115:2490- 2496.
47. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-1471.
48. Hedegaard SS, Hvas AM, Grove EL, et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res 2009;124:96-100.
49. Grauer G F, Rose BJ, Toolan L, et al. Effects of low-dose aspirin and specifc thromboxane synthetase inhibition on whole blood platelet aggregation and adenosine triphosphate secretion in healthy dogs. Am J Vet Res 1992;53:1631-1635.